Key Drivers
- High ROIC
- Strong FCF
- Weak liquidity
AIAI Summary
Haleon has shifted from a volume roll‑up into a margin‑ and free‑cash‑flow–driven platform, so the stock is now a quality‑cashflow, execution‑sensitive investment where successful premiumisation/SKU rationalisation and timely debt reduction are the critical upside drivers while missed organic growth or refinancing stress could trigger impairments and multiple compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High ROIC
- •Strong FCF
- •Weak liquidity
HLN delivers robust profitability and cash generation (high ROIC, 24% EBITDA margin, $2.3B FCF) but faces near-term liquidity strain and concentrated long-term debt with a thin tangible equity buffer.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Near $10.00 support
- •Resistance $11.00–$11.27
HLN is in a short-term downtrend—down ~10.7% over the last month and trading below the last-month SMA, sitting near support around $10.00 but still facing resistance at $11.00–$11.27, so wait for support to hold or a breakout above resistance before a bullish entry.
~10.7% drop from $11.27 to $10.07 over the last month, signaling selling pressure
Sentiment & News
Key News Insights:
- •Sales miss
- •Profit/cash strength
- •China expansion
Haleon's Q4 sales missed expectations and dented the stock, but double‑digit profit growth, strong cash generation, new product launches, a China manufacturing investment and supportive research/analyst signals keep the strategic growth case intact.
The mix of near‑term sales pressure and solid profitability means the stock may face short‑term headwinds but retains upside if new product and China strategies translate into revenue recovery
Similar Companies in Healthcare
Other companies in the same sector with AI ratings